EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review

Adriana Gardner iD, Paul Nieberg, George Sakoulas iD, Annie Wong-Beringer iD

JAC-Antimicrobial Resistance · 04.03.2025 · 7 (2)

DOI: 10.1093/jacamr/dlaf022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 08.03.2025. Verfasst von Adriana Gardner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huntington Health, Pasadena, CA, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased carbapenem prescribing has contributed to rising rates of carbapenem-resistant bacterial pathogens. Although antimicrobial stewardship efforts that facilitate de-escalation of carbapenems to alternative agents can minimize unnecessary exposure, clinicians may be hesitant to de-escalate therapy due to concerns for potentially compromising patient outcomes. A literature search was performed to characterize carbapenem de-escalation strategies and assess associated patient outcomes. A total of 228 articles were screened on PubMed, and 15 studies that examine the de-escalation of carbapenems to non-carbapenem alternatives were identified for inclusion. The studies primarily included non–critically ill and immunocompetent adults involving over 5000 patients receiving carbapenem therapy for a variety of infections, most commonly urinary tract infections, pneumonia, and skin and soft tissue infections. Twelve of 15 studies reported carbapenem de-escalation as part of their antimicrobial stewardship programme (ASP) initiatives. Overall, carbapenem de-escalation led to a reduction in carbapenem use by 2 to 5 days and was not associated with negative outcomes (higher rates of clinical failure or mortality) compared with the continuation groups. Baseline characteristics of patient age, comorbidities, severity of illness, infection site and pathogen were not consistently described or balanced between groups, which may bias results in favour of de-escalation. Identification of which patients to consider for antibiotic de-escalation is nuanced and requires careful consideration of complex patient history, infection type, clinical stability and microbiology results. Although findings support carbapenem de-escalation as a promising ASP strategy, more high-quality studies are needed to more definitely elucidate the impact of carbapenem de-escalation on clinical outcomes.

Autor:innen und Institutionen

  • Department of Pharmacy, Huntington Health, Pasadena, CA, USA.
  • Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, CA, USA.
  • Department of Medicine-Infectious Diseases, Huntington Health, Pasadena, CA, USA.
  • Department of Infectious Diseases, Sharp Rees Stealy Medical Group, San Diego, CA, USA.
  • University of California San Diego School of Medicine, La Jolla, CA, USA.

ORCID-Profile: Adriana Gardner, George Sakoulas, Annie Wong-Beringer

Zitieren

APA

Gardner, A., Nieberg, P., Sakoulas, G., & Wong-Beringer, A. (2025). Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review. JAC-Antimicrobial Resistance, 7(2). https://doi.org/10.1093/jacamr/dlaf022

Vancouver

Gardner A, Nieberg P, Sakoulas G, Wong-Beringer A. Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review. JAC-Antimicrobial Resistance. 2025;7(2). doi:10.1093/jacamr/dlaf022

BibTeX
@article{Gardner2025,
  author = {Gardner, Adriana and Nieberg, Paul and Sakoulas, George and Wong-Beringer, Annie},
  title = {Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review},
  journal = {JAC-Antimicrobial Resistance},
  year = {2025},
  volume = {7},
  number = {2},
  doi = {10.1093/jacamr/dlaf022}
}
Kostenlos starten →